サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1239534

尿路感染症（UTI）検査市場：感染症タイプ別、検査タイプ別、エンドユーザー別、検査キット別：世界の機会分析と産業予測、2021-2031年

Urinary Tract Infection Testing Market By Infection Type, By Test Type, By End User, By Test Kit : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 280 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
尿路感染症（UTI）検査市場：感染症タイプ別、検査タイプ別、エンドユーザー別、検査キット別：世界の機会分析と産業予測、2021-2031年
出版日: 2023年01月01日
発行: Allied Market Research
ページ情報: 英文 280 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の尿路感染症（UTI）検査市場は、2022年から2031年にかけてCAGR6.2%で2021年の5億7,400万米ドルから増加し、2031年には10億2,740万米ドルに達すると予測されています。

腎臓病や糖尿病などの慢性疾患の有病率の上昇、完全な尿分析を好む臨床医の増加、疾患の早期発見に対する需要の急増、院内尿路感染症（UTI）の症例の増加、尿分析検査の使用の増加が、尿分析検査市場の成長を促進する主な要因となっています。また、低侵襲な尿診断法に対する需要の高まり、高度な尿分析検査法の採用の増加、新規かつ正確な診断検査の導入に向けた研究開発活動の活発化なども、尿路感染症（UTI）検査市場の成長を支える要因となっています。

尿路感染症（UTI）検査の世界市場は、尿路感染症（UTI）治療薬の使用に伴う副作用のため、市場開拓の課題が予想されます。尿路感染症（UTI）検査の診断と管理における頻繁なエラーは、予測期間中の市場拡大を阻害する可能性があります。UTIに関連する症状が特定できないこと、標準的な診断基準がないこと、サンプルの汚染が多いことなどは、市場拡大の主な障害となっています。

尿路感染症（UTI）は、女性、妊娠中、閉経前後の女性でよく見られる症状です。尿路感染症（UTI）は、重篤な罹患率や死亡率に関連し、罹患者のQOLに影響を及ぼします。抗生物質療法は、症状の持続期間を短縮する成功した治療法です。耐性菌の発生、抗生物質の望ましくない作用、その他の関連する問題から、尿路結石を管理する代替手段を発見するための研究枠組みが確立されています。

自然療法は、症状を緩和し、健康全般を改善するために、多くの病気の治療に広く用いられています。最近、多くの病気の治療と予防に薬草が使用されるようになりました。薬草を用いた補完療法は、特別に考慮すべき研究テーマであると思われます。ある種の尿路結石の管理に薬草療法が有用であることが実証されています。

非抗生物質による治療は、尿路結石の発症確率を下げ、その症状を軽減するための良い戦略です。天然成分、ミネラル、プロバイオティクスは、注目されているいくつかの薬剤の一つです。これらの薬剤はそれぞれ別のメカニズムで作用するため、1回分の投与量に薬剤を共配合することで、尿路結石の管理における予防と治療の両方の方法に有用な天然製剤を作ることができます。

COVID-19のパンデミックはいくつかの不確定要素をもたらし、世界中のさまざまなビジネスが停止し、深刻な経済的損失につながっています。COVID-19の流行は、製造業やサプライチェーン・物流業に悪影響を及ぼし、ヘルスケア事業にも悪影響を及ぼしました。政府やヘルスケアプロバイダーは、COVID-19のために前例のない問題に直面しており、規制環境や手続きにも影響を及ぼしています。COVID-19を発症して入院した患者は、尿路感染症（UTI）と診断されたと報告されています。しかし、複数の検査で、COVID-19の患者さんには重度の尿路症状がないことが判明しています。COVID-19の患者さんでは、血中反応性蛋白やプロカルシトニンなどの細菌感染の炎症指標が高いため、抗生物質が多用されています。しかし、これらの個体の大部分は、微生物学的に確認された細菌性共同感染症状を有していました。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な影響要因
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 市場におけるCOVID-19影響分析
  • 主な規制分析
  • 市場シェア分析
  • 特許情勢
  • 規制ガイドライン
  • バリューチェーン分析

第4章 尿路感染症（UTI）検査市場：感染症タイプ別

  • 概要
    • 市場規模と予測
  • 尿道炎
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • 膀胱炎
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • 腎盂腎炎
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別

第5章 尿路感染症（UTI）検査市場：検査タイプ別

  • 概要
    • 市場規模と予測
  • 尿検査
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • 尿培養
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • 感受性試験
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別

第6章 尿路感染症（UTI）検査市場：エンドユーザー別

  • 概要
    • 市場規模と予測
  • 病院
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • 診断検査室
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • 研究機関
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別

第7章 尿路感染症（UTI）検査市場：検査キット別

  • 概要
    • 市場規模と予測
  • ホーム検査キット
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • 検査キット
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別

第8章 尿路感染症（UTI）検査市場：地域別

  • 概要
    • 市場規模と予測：地域別
  • 北米
    • 主な動向と機会
    • 市場規模と予測：感染症タイプ別
    • 市場規模と予測：検査タイプ別
    • 市場規模と予測：エンドユーザー別
    • 市場規模と予測：検査キット別
    • 市場規模と予測：国別
      • 米国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • カナダ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • メキシコ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
  • 欧州
    • 主な動向と機会
    • 市場規模と予測：感染症タイプ別
    • 市場規模と予測：検査タイプ別
    • 市場規模と予測：エンドユーザー別
    • 市場規模と予測：検査キット別
    • 市場規模と予測：国別
      • ドイツ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • 英国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • フランス
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • スペイン
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • イタリア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • その他欧州
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
  • アジア太平洋
    • 主な動向と機会
    • 市場規模と予測：感染症タイプ別
    • 市場規模と予測：検査タイプ別
    • 市場規模と予測：エンドユーザー別
    • 市場規模と予測：検査キット別
    • 市場規模と予測：国別
      • 中国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • 日本
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • インド
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • 韓国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • オーストラリア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • その他アジア太平洋地域
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
  • ラテンアメリカ・中東・アフリカ
    • 主な動向と機会
    • 市場規模と予測：感染症タイプ別
    • 市場規模と予測：検査タイプ別
    • 市場規模と予測：エンドユーザー別
    • 市場規模と予測：検査キット別
    • 市場規模と予測：国別
      • ブラジル
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • サウジアラビア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • アラブ首長国連邦
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • 南アフリカ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別
      • その他のラテンアメリカ・中東・アフリカ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：感染症タイプ別
      • 市場規模と予測：検査タイプ別
      • 市場規模と予測：エンドユーザー別
      • 市場規模と予測：検査キット別

第9章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • トップ 10プレーヤーの製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • トッププレーヤーのポジショニング、2021

第10章 企業プロファイル

  • Abbott Laboratories
  • Roche AG
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories
  • Danaher Corporation
  • ACON Laboratories Inc.
  • Cardinal Health Inc.
  • Stryker Corporation
  • SYSMEX CORPORATION
  • LabCorp（Laboratory Corporation of America Holdings）.
図表

LIST OF TABLES

  • TABLE 01. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. URINARY TRACT INFECTION TESTING MARKET FOR URETHRITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. URINARY TRACT INFECTION TESTING MARKET FOR CYSTITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. URINARY TRACT INFECTION TESTING MARKET FOR PYELONEPHRITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. URINARY TRACT INFECTION TESTING MARKET FOR URINALYSIS , BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. URINARY TRACT INFECTION TESTING MARKET FOR URINE CULTURES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. URINARY TRACT INFECTION TESTING MARKET FOR SUSCEPTIBILITY TESTING, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. URINARY TRACT INFECTION TESTING MARKET FOR HOSPITALS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. URINARY TRACT INFECTION TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. URINARY TRACT INFECTION TESTING MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. URINARY TRACT INFECTION TESTING MARKET FOR HOME TEST KITS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. URINARY TRACT INFECTION TESTING MARKET FOR LABORATORY TEST KITS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. URINARY TRACT INFECTION TESTING MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. U.S. URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. U.S. URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. U.S. URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. U.S. URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. CANADA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. CANADA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. CANADA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. CANADA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. UK URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. UK URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. UK URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. UK URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. ITALY URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. ITALY URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. ITALY URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. ITALY URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. CHINA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. CHINA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. CHINA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. CHINA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. INDIA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. INDIA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. INDIA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. INDIA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 91. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 92. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 93. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 94. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 95. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 96. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 97. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 98. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 99. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 100. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 101. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 102. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 103. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 104. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 105. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 106. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 107. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 108. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 109. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 110. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 111. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 112. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 113. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 114. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 115. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 116. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 117. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 118. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 119. ROCHE AG: KEY EXECUTIVES
  • TABLE 120. ROCHE AG: COMPANY SNAPSHOT
  • TABLE 121. THERMO FISHER SCIENTIFIC, INC.: KEY EXECUTIVES
  • TABLE 122. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 123. BIO-RAD LABORATORIES: KEY EXECUTIVES
  • TABLE 124. BIO-RAD LABORATORIES: COMPANY SNAPSHOT
  • TABLE 125. DANAHER CORPORATION: KEY EXECUTIVES
  • TABLE 126. DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 127. ACON LABORATORIES INC.: KEY EXECUTIVES
  • TABLE 128. ACON LABORATORIES INC.: COMPANY SNAPSHOT
  • TABLE 129. CARDINAL HEALTH INC.: KEY EXECUTIVES
  • TABLE 130. CARDINAL HEALTH INC.: COMPANY SNAPSHOT
  • TABLE 131. STRYKER CORPORATION: KEY EXECUTIVES
  • TABLE 132. STRYKER CORPORATION: COMPANY SNAPSHOT
  • TABLE 133. SYSMEX CORPORATION: KEY EXECUTIVES
  • TABLE 134. SYSMEX CORPORATION: COMPANY SNAPSHOT
  • TABLE 135. LABCORP(LABORATORY CORPORATION OF AMERICA HOLDINGS).: KEY EXECUTIVES
  • TABLE 136. LABCORP(LABORATORY CORPORATION OF AMERICA HOLDINGS).: COMPANY SNAPSHOT

LIST OF FIGURES

  • FIGURE 01. URINARY TRACT INFECTION TESTING MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF URINARY TRACT INFECTION TESTING MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN URINARY TRACT INFECTION TESTING MARKET (2022-2031)
  • FIGURE 04. PORTER FIVE-1
  • FIGURE 05. PORTER FIVE-2
  • FIGURE 06. PORTER FIVE-3
  • FIGURE 07. PORTER FIVE-4
  • FIGURE 08. PORTER FIVE-5
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALURINARY TRACT INFECTION TESTING MARKET
  • FIGURE 10. IMPACT OF KEY REGULATION: URINARY TRACT INFECTION TESTING MARKET
  • FIGURE 11. MARKET SHARE ANALYSIS: URINARY TRACT INFECTION TESTING MARKET
  • FIGURE 12. PATENT ANALYSIS BY COMPANY
  • FIGURE 13. PATENT ANALYSIS BY COUNTRY
  • FIGURE 14. REGULATORY GUIDELINES: URINARY TRACT INFECTION TESTING MARKET
  • FIGURE 15. VALUE CHAIN ANALYSIS: URINARY TRACT INFECTION TESTING MARKET
  • FIGURE 16. URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR URETHRITIS, BY COUNTRY 2021-2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR CYSTITIS, BY COUNTRY 2021-2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR PYELONEPHRITIS, BY COUNTRY 2021-2031(%)
  • FIGURE 20. URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR URINALYSIS , BY COUNTRY 2021-2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR URINE CULTURES, BY COUNTRY 2021-2031(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR SUSCEPTIBILITY TESTING, BY COUNTRY 2021-2031(%)
  • FIGURE 24. URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR HOSPITALS, BY COUNTRY 2021-2031(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY 2021-2031(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR RESEARCH INSTITUTES, BY COUNTRY 2021-2031(%)
  • FIGURE 28. URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021(%)
  • FIGURE 29. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR HOME TEST KITS, BY COUNTRY 2021-2031(%)
  • FIGURE 30. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR LABORATORY TEST KITS, BY COUNTRY 2021-2031(%)
  • FIGURE 31. URINARY TRACT INFECTION TESTING MARKET BY REGION, 2021
  • FIGURE 32. U.S. URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. CANADA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. MEXICO URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. GERMANY URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. UK URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. FRANCE URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. SPAIN URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. ITALY URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. CHINA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. JAPAN URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. INDIA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 44. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 45. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 46. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 47. BRAZIL URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 48. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 49. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 50. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 51. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 52. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 53. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 54. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 55. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 56. COMPETITIVE DASHBOARD
  • FIGURE 57. COMPETITIVE HEATMAP: URINARY TRACT INFECTION TESTING MARKET
  • FIGURE 58. TOP PLAYER POSITIONING, 2021
目次
Product Code: A31362

The global urinary tract infection testing market is anticipated to reach $1,027.4 million by 2031, increasing from $574 million in 2021 at a CAGR of 6.2% from 2022 to 2031.

The rise in the prevalence of chronic diseases such as kidney disease and diabetes, an increase in the preference of clinicians for complete urine analysis, the surge in demand for early disease detection, a rise in cases of hospital-acquired urinary tract infection, and an increase in the use of urine analysis tests are the key factors driving the growth of the urinalysis test market. In addition, the rise in demand for minimally invasive urine diagnostic procedures, the increase in adoption of advanced urine analysis testing procedures, and the surge in R&D activities for the introduction of novel and accurate diagnostic tests are some factors that support the growth of the UTI testing market.

The global market for urinary tract infection testing is anticipated to experience development challenges due to side effects associated with the usage of UTI medications. Frequent errors in the diagnosis and management of urinary tract infection testing can impede market expansion during the forecast period. The lack of identifiable symptoms associated with UTI, the absence of standard diagnostic criteria, and the high contamination of samples are some of the key hurdles to market expansion.

Urinary tract infection (UTI) is a common occurrence in females, during pregnancy, and in peri- and postmenopausal women. UTIs are associated with severe morbidity and death, and they impact the quality of life of the affected people. Antibiotic therapy is a successful treatment that shortens the duration of symptoms. The development of resistance, the undesirable effects of antibiotics, and other linked issues lead to the establishment of a research framework to discover alternate means to managing UTIs.

Natural techniques are widely employed in the treatment of numerous ailments to alleviate symptoms and improve overall health.The use of medicinal herbs in the treatment and prevention of numerous diseases has expanded recently]. Complimentary therapy with medicinal herbs is a study topic that may merit special consideration. It has been demonstrated that herbal remedies can be useful in the management of a certain form of UTI.

Treatment with non-antibiotic drugs is a good strategy to lower the chance of developing UTI and to decrease its symptoms. Natural elements, minerals, and probiotics are among several agents that draw interest. Co-formulation of medications in a single dose form can create a natural formulation that is useful for both preventive and therapeutic methods in the management of UTI because each of these medications operates through a separate mechanism.

The COVID-19 pandemic brought several uncertainties, leading to severe economic losses as various businesses across the world were at a standstill. The arrival of the COVID-19 pandemic negatively impacted the manufacturing and supply chain & logistics industries, adversely affecting the healthcare business. Governments and healthcare providers are facing unheard-of issues owing to COVID-19, which has also had an impact on the regulatory environment and procedures. Patients with COVID-19 who were hospitalized were reportedly diagnosed with urinary tract infections. But multiple examinations have revealed that people with COVID-19 did not have severe urinary tract symptoms. Antibiotics are used extensively in COVID-19 patients due to high levels of blood inflammatory indicators of bacterial infection such as elevated C-reactive protein and procalcitonin. The majority of these individuals, however, had microbiologically verified bacterial co-infection symptoms.

The key players profiled in the report include F. Hoffmann-La Roche Ltd, Stryker, Abbott, Siemens, Sysmex Corporation, Cardinal Health, Danaher, Quidel, Bio-Rad Laboratories, Inc., and ACON Labs.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the urinary tract infection testing market analysis from 2021 to 2031 to identify the prevailing urinary tract infection testing market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the urinary tract infection testing market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global urinary tract infection testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Test Kit

  • Home Test Kits
  • Laboratory Test Kits

By Infection Type

  • Urethritis
  • Cystitis
  • Pyelonephritis

By Test Type

  • Urinalysis 
  • Urine Cultures
  • Susceptibility Testing

By End User

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • United Arab Emirates
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories
  • Danaher Corporation
  • ACON Laboratories Inc.
  • Cardinal Health Inc.
  • Stryker Corporation
  • SYSMEX CORPORATION
  • Abbott Laboratories
  • Roche AG
  • LabCorp(Laboratory Corporation of America Holdings).

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities
  • 3.5. COVID-19 Impact Analysis on the market
  • 3.6. Key Regulation Analysis
  • 3.7. Market Share Analysis
  • 3.8. Patent Landscape
  • 3.9. Regulatory Guidelines
  • 3.10. Value Chain Analysis

CHAPTER 4: URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Urethritis
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Cystitis
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Pyelonephritis
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Urinalysis 
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Urine Cultures
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Susceptibility Testing
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: URINARY TRACT INFECTION TESTING MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Diagnostic Laboratories
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Research Institutes
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Home Test Kits
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Laboratory Test Kits
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country

CHAPTER 8: URINARY TRACT INFECTION TESTING MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key trends and opportunities
    • 8.2.2. Market size and forecast, by Infection Type
    • 8.2.3. Market size and forecast, by Test Type
    • 8.2.4. Market size and forecast, by End User
    • 8.2.5. Market size and forecast, by Test Kit
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Key market trends, growth factors and opportunities
      • 8.2.6.1.2. Market size and forecast, by Infection Type
      • 8.2.6.1.3. Market size and forecast, by Test Type
      • 8.2.6.1.4. Market size and forecast, by End User
      • 8.2.6.1.5. Market size and forecast, by Test Kit
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Key market trends, growth factors and opportunities
      • 8.2.6.2.2. Market size and forecast, by Infection Type
      • 8.2.6.2.3. Market size and forecast, by Test Type
      • 8.2.6.2.4. Market size and forecast, by End User
      • 8.2.6.2.5. Market size and forecast, by Test Kit
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Key market trends, growth factors and opportunities
      • 8.2.6.3.2. Market size and forecast, by Infection Type
      • 8.2.6.3.3. Market size and forecast, by Test Type
      • 8.2.6.3.4. Market size and forecast, by End User
      • 8.2.6.3.5. Market size and forecast, by Test Kit
  • 8.3. Europe
    • 8.3.1. Key trends and opportunities
    • 8.3.2. Market size and forecast, by Infection Type
    • 8.3.3. Market size and forecast, by Test Type
    • 8.3.4. Market size and forecast, by End User
    • 8.3.5. Market size and forecast, by Test Kit
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Key market trends, growth factors and opportunities
      • 8.3.6.1.2. Market size and forecast, by Infection Type
      • 8.3.6.1.3. Market size and forecast, by Test Type
      • 8.3.6.1.4. Market size and forecast, by End User
      • 8.3.6.1.5. Market size and forecast, by Test Kit
      • 8.3.6.2. UK
      • 8.3.6.2.1. Key market trends, growth factors and opportunities
      • 8.3.6.2.2. Market size and forecast, by Infection Type
      • 8.3.6.2.3. Market size and forecast, by Test Type
      • 8.3.6.2.4. Market size and forecast, by End User
      • 8.3.6.2.5. Market size and forecast, by Test Kit
      • 8.3.6.3. France
      • 8.3.6.3.1. Key market trends, growth factors and opportunities
      • 8.3.6.3.2. Market size and forecast, by Infection Type
      • 8.3.6.3.3. Market size and forecast, by Test Type
      • 8.3.6.3.4. Market size and forecast, by End User
      • 8.3.6.3.5. Market size and forecast, by Test Kit
      • 8.3.6.4. Spain
      • 8.3.6.4.1. Key market trends, growth factors and opportunities
      • 8.3.6.4.2. Market size and forecast, by Infection Type
      • 8.3.6.4.3. Market size and forecast, by Test Type
      • 8.3.6.4.4. Market size and forecast, by End User
      • 8.3.6.4.5. Market size and forecast, by Test Kit
      • 8.3.6.5. Italy
      • 8.3.6.5.1. Key market trends, growth factors and opportunities
      • 8.3.6.5.2. Market size and forecast, by Infection Type
      • 8.3.6.5.3. Market size and forecast, by Test Type
      • 8.3.6.5.4. Market size and forecast, by End User
      • 8.3.6.5.5. Market size and forecast, by Test Kit
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Key market trends, growth factors and opportunities
      • 8.3.6.6.2. Market size and forecast, by Infection Type
      • 8.3.6.6.3. Market size and forecast, by Test Type
      • 8.3.6.6.4. Market size and forecast, by End User
      • 8.3.6.6.5. Market size and forecast, by Test Kit
  • 8.4. Asia-Pacific
    • 8.4.1. Key trends and opportunities
    • 8.4.2. Market size and forecast, by Infection Type
    • 8.4.3. Market size and forecast, by Test Type
    • 8.4.4. Market size and forecast, by End User
    • 8.4.5. Market size and forecast, by Test Kit
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. China
      • 8.4.6.1.1. Key market trends, growth factors and opportunities
      • 8.4.6.1.2. Market size and forecast, by Infection Type
      • 8.4.6.1.3. Market size and forecast, by Test Type
      • 8.4.6.1.4. Market size and forecast, by End User
      • 8.4.6.1.5. Market size and forecast, by Test Kit
      • 8.4.6.2. Japan
      • 8.4.6.2.1. Key market trends, growth factors and opportunities
      • 8.4.6.2.2. Market size and forecast, by Infection Type
      • 8.4.6.2.3. Market size and forecast, by Test Type
      • 8.4.6.2.4. Market size and forecast, by End User
      • 8.4.6.2.5. Market size and forecast, by Test Kit
      • 8.4.6.3. India
      • 8.4.6.3.1. Key market trends, growth factors and opportunities
      • 8.4.6.3.2. Market size and forecast, by Infection Type
      • 8.4.6.3.3. Market size and forecast, by Test Type
      • 8.4.6.3.4. Market size and forecast, by End User
      • 8.4.6.3.5. Market size and forecast, by Test Kit
      • 8.4.6.4. South Korea
      • 8.4.6.4.1. Key market trends, growth factors and opportunities
      • 8.4.6.4.2. Market size and forecast, by Infection Type
      • 8.4.6.4.3. Market size and forecast, by Test Type
      • 8.4.6.4.4. Market size and forecast, by End User
      • 8.4.6.4.5. Market size and forecast, by Test Kit
      • 8.4.6.5. Australia
      • 8.4.6.5.1. Key market trends, growth factors and opportunities
      • 8.4.6.5.2. Market size and forecast, by Infection Type
      • 8.4.6.5.3. Market size and forecast, by Test Type
      • 8.4.6.5.4. Market size and forecast, by End User
      • 8.4.6.5.5. Market size and forecast, by Test Kit
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Key market trends, growth factors and opportunities
      • 8.4.6.6.2. Market size and forecast, by Infection Type
      • 8.4.6.6.3. Market size and forecast, by Test Type
      • 8.4.6.6.4. Market size and forecast, by End User
      • 8.4.6.6.5. Market size and forecast, by Test Kit
  • 8.5. LAMEA
    • 8.5.1. Key trends and opportunities
    • 8.5.2. Market size and forecast, by Infection Type
    • 8.5.3. Market size and forecast, by Test Type
    • 8.5.4. Market size and forecast, by End User
    • 8.5.5. Market size and forecast, by Test Kit
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Key market trends, growth factors and opportunities
      • 8.5.6.1.2. Market size and forecast, by Infection Type
      • 8.5.6.1.3. Market size and forecast, by Test Type
      • 8.5.6.1.4. Market size and forecast, by End User
      • 8.5.6.1.5. Market size and forecast, by Test Kit
      • 8.5.6.2. Saudi Arabia
      • 8.5.6.2.1. Key market trends, growth factors and opportunities
      • 8.5.6.2.2. Market size and forecast, by Infection Type
      • 8.5.6.2.3. Market size and forecast, by Test Type
      • 8.5.6.2.4. Market size and forecast, by End User
      • 8.5.6.2.5. Market size and forecast, by Test Kit
      • 8.5.6.3. United Arab Emirates
      • 8.5.6.3.1. Key market trends, growth factors and opportunities
      • 8.5.6.3.2. Market size and forecast, by Infection Type
      • 8.5.6.3.3. Market size and forecast, by Test Type
      • 8.5.6.3.4. Market size and forecast, by End User
      • 8.5.6.3.5. Market size and forecast, by Test Kit
      • 8.5.6.4. South Africa
      • 8.5.6.4.1. Key market trends, growth factors and opportunities
      • 8.5.6.4.2. Market size and forecast, by Infection Type
      • 8.5.6.4.3. Market size and forecast, by Test Type
      • 8.5.6.4.4. Market size and forecast, by End User
      • 8.5.6.4.5. Market size and forecast, by Test Kit
      • 8.5.6.5. Rest of LAMEA
      • 8.5.6.5.1. Key market trends, growth factors and opportunities
      • 8.5.6.5.2. Market size and forecast, by Infection Type
      • 8.5.6.5.3. Market size and forecast, by Test Type
      • 8.5.6.5.4. Market size and forecast, by End User
      • 8.5.6.5.5. Market size and forecast, by Test Kit

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top player positioning, 2021

CHAPTER 10: COMPANY PROFILES

  • 10.1. Abbott Laboratories
    • 10.1.1. Company overview
    • 10.1.2. Key Executives
    • 10.1.3. Company snapshot
  • 10.2. Roche AG
    • 10.2.1. Company overview
    • 10.2.2. Key Executives
    • 10.2.3. Company snapshot
  • 10.3. Thermo Fisher Scientific, Inc.
    • 10.3.1. Company overview
    • 10.3.2. Key Executives
    • 10.3.3. Company snapshot
  • 10.4. Bio-Rad Laboratories
    • 10.4.1. Company overview
    • 10.4.2. Key Executives
    • 10.4.3. Company snapshot
  • 10.5. Danaher Corporation
    • 10.5.1. Company overview
    • 10.5.2. Key Executives
    • 10.5.3. Company snapshot
  • 10.6. ACON Laboratories Inc.
    • 10.6.1. Company overview
    • 10.6.2. Key Executives
    • 10.6.3. Company snapshot
  • 10.7. Cardinal Health Inc.
    • 10.7.1. Company overview
    • 10.7.2. Key Executives
    • 10.7.3. Company snapshot
  • 10.8. Stryker Corporation
    • 10.8.1. Company overview
    • 10.8.2. Key Executives
    • 10.8.3. Company snapshot
  • 10.9. SYSMEX CORPORATION
    • 10.9.1. Company overview
    • 10.9.2. Key Executives
    • 10.9.3. Company snapshot
  • 10.10. LabCorp(Laboratory Corporation of America Holdings).
    • 10.10.1. Company overview
    • 10.10.2. Key Executives
    • 10.10.3. Company snapshot